Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
Enveric Biosciences (NASDAQ: ENVB) has announced that its subsidiary, Akos Biosciences, has entered into two licensing agreements with Restoration Biologics for cannabinoid-COX-2 conjugate compounds. The agreements cover both pharmaceutical and non-pharmaceutical applications for human and animal use, primarily focusing on joint pathologies like osteoarthritis and rheumatoid arthritis.
The exclusive, global licenses grant Restoration Biologics full development, marketing, and commercialization rights. The agreements include potential milestone payments totaling $61 million for the pharmaceutical license and $21 million for the non-pharmaceutical license. Royalty rates range from low single digit to low double digits on future sales, contingent on meeting specific sales criteria.
Enveric Biosciences (NASDAQ: ENVB) ha annunciato che la sua filiazione, Akos Biosciences, ha stipulato due accordi di licenza con Restoration Biologics per composti coniugati cannabinoide-COX-2. Gli accordi coprono sia applicazioni farmaceutiche che non, per uso umano e animale, concentrandosi principalmente sulle patologie articolari come l'osteoartrite e l'artrite reumatoide.
Le licenze esclusive e globali concedono a Restoration Biologics pieni diritti di sviluppo, marketing e commercializzazione. Gli accordi includono potenziali pagamenti per traguardi che ammontano a 61 milioni di dollari per la licenza farmaceutica e 21 milioni di dollari per la licenza non farmaceutica. Le aliquote di royalty variano da basse cifre singole a basse cifre doppie sulle vendite future, a condizione di soddisfare specifici criteri di vendita.
Enveric Biosciences (NASDAQ: ENVB) ha anunciado que su subsidiaria, Akos Biosciences, ha firmado dos acuerdos de licencia con Restoration Biologics para compuestos conjugados de cannabinoides-COX-2. Los acuerdos cubren tanto aplicaciones farmacéuticas como no farmacéuticas para uso humano y animal, centrándose principalmente en patologías articulares como la osteoartritis y la artritis reumatoide.
Las licencias exclusivas y globales otorgan a Restoration Biologics derechos totales de desarrollo, comercialización y comercialización. Los acuerdos incluyen posibles pagos por hitos que totalizan 61 millones de dólares para la licencia farmacéutica y 21 millones de dólares para la licencia no farmacéutica. Las tasas de regalías varían de cifras bajas de un solo dígito a cifras bajas de dos dígitos en ventas futuras, dependiendo de cumplir con criterios específicos de ventas.
엔베릭 바이오사이언스 (NASDAQ: ENVB)는 그 자회사인 아코스 바이오사이언스가 레스토레이션 바이오로직스와 함께 칸나비노이드-COX-2 결합 화합물에 대한 두 개의 라이센스 계약을 체결했다고 발표했습니다. 이 계약은 주로 골관절염과 류마티스 관절염과 같은 관절 질환에 초점을 맞추어 사람 및 동물 용도의 제약 및 비제약 응용 프로그램을 모두 다룹니다.
독점적이고 글로벌한 라이센스는 레스토레이션 바이오로직스에 개발, 마케팅 및 상업화에 대한 전적인 권리를 부여합니다. 이 계약에는 제약 라이센스에 대해 6100만 달러와 비제약 라이센스에 대해 2100만 달러의 잠재적 이정표 지급이 포함됩니다. 로열티 비율은 특정 판매 기준을 충족하는 경우 향후 판매에서 낮은 단일 자릿수에서 낮은 이중 자릿수 사이로 변동합니다.
Enveric Biosciences (NASDAQ: ENVB) a annoncé que sa filiale, Akos Biosciences, a conclu deux accords de licence avec Restoration Biologics pour des composés conjugués cannabinoïde-COX-2. Les accords couvrent à la fois des applications pharmaceutiques et non pharmaceutiques pour un usage humain et animal, se concentrant principalement sur les pathologies articulaires telles que l'arthrose et l'arthrite rhumatoïde.
Les licences exclusives et mondiales accordent à Restoration Biologics tous les droits de développement, de marketing et de commercialisation. Les accords comprennent des paiements d'étape potentiels totalisant 61 millions de dollars pour la licence pharmaceutique et 21 millions de dollars pour la licence non pharmaceutique. Les taux de redevances varient de faibles chiffres à un seul chiffre à de faibles chiffres à deux chiffres sur les ventes futures, sous réserve du respect de critères spécifiques de vente.
Enveric Biosciences (NASDAQ: ENVB) hat bekannt gegeben, dass ihre Tochtergesellschaft, Akos Biosciences, zwei Lizenzverträge mit Restoration Biologics für cannabinoid-COX-2-Konjugate abgeschlossen hat. Die Vereinbarungen decken sowohl pharmazeutische als auch nicht-pharmazeutische Anwendungen für den menschlichen und tierischen Gebrauch ab und konzentrieren sich hauptsächlich auf Gelenkpathologien wie Osteoarthritis und rheumatoide Arthritis.
Die exklusiven, globalen Lizenzen gewähren Restoration Biologics vollständige Entwicklungs-, Marketing- und Kommerzialisierungsrechte. Die Vereinbarungen umfassen potenzielle Meilensteinzahlungen in Höhe von 61 Millionen Dollar für die pharmazeutische Lizenz und 21 Millionen Dollar für die nicht-pharmazeutische Lizenz. Die Lizenzgebühren liegen bei niedrigen einstelligen bis niedrigen zweistelligen Prozentsätzen auf zukünftige Verkäufe, abhängig von der Erfüllung bestimmter Verkaufsbedingungen.
- Potential milestone payments totaling $82 million ($61M pharmaceutical + $21M non-pharmaceutical)
- Royalty rates ranging from low single digit to low double digits on future sales
- Global exclusive licensing rights secured for both pharmaceutical and non-pharmaceutical applications
- Revenue generation dependent on successful product development and commercialization
- Milestone payments are conditional and not guaranteed
Insights
This licensing deal marks a significant strategic and financial milestone for Enveric Biosciences, potentially generating up to
The credibility of Restoration Biologics is reinforced by their leadership team, including Dr. William D. Bugbee from Scripps Institute and Dr. Farsh Guilak, both renowned experts in joint restoration and regenerative medicine. This expertise significantly increases the probability of successful development and commercialization.
The deal's structure is particularly strategic as it:
- Maintains upside potential through milestone payments and royalties without requiring additional R&D investment from Enveric
- Expands the application of Enveric's technology into the lucrative joint disease market, including both osteoarthritis and rheumatoid arthritis
- Represents the third and fourth out-licensing deals from Enveric's portfolio, demonstrating consistent execution of their asset monetization strategy
The dual-license approach (pharmaceutical and non-pharmaceutical) maximizes the technology's commercial potential while diversifying development risk. This deal structure aligns with industry best practices for biotech licensing and suggests sophisticated deal-making capabilities from Enveric's management team.
Licensee, Restoration Biologics, is uniquely positioned to advance care in treating joint disease
The two licenses grant Restoration Biologics use of the technology for all human and animal applications. Restoration Biologics initially plans to focus on joint pathology, such as osteoarthritis and rheumatoid arthritis. The two exclusive, royalty-bearing global licenses provide full control to Restoration Biologics to develop, market, and commercialize the conjugate compounds, which are novel chemical structures that include cannabinoids in conjugate form with COX-2 inhibitors and cannabinoids in conjugate form with selected steroids.
Under these licenses, Enveric, through its subsidiary, Akos, may receive future development and sales milestone payments, assuming certain conditions are met, including successful product development and commercialization. Royalty rate percentages are tiered, depending on meeting certain sales criteria, and range from low single digit to low double digits on future sales. These milestone payments could potentially add up to a total of
“Restoration Biologics is a young and innovative biotechnology company with nationally recognized experts, and we are very pleased that it has partnered with Enveric to advance the development of these important health care products,” said Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric. “We look forward to working with Restoration Biologics, and we are confident in their leadership and capabilities to further develop the conjugate compounds for both pharmaceutical and potential non-pharmaceutical applications, expanding treatment options for patients with joint disease. Executing these next two license agreements once again supports the value of Enveric’s extensive portfolio of assets, following the two previously announced out-license agreements for Enveric’s patented CBD topical product and EB-002 drug candidate.”
“This opportunity presents an exciting and novel approach to the treatment of joint disease and potentially the enhancement of biological implants for patients suffering with joint injuries,” said Suzanne Tabbaa, Ph.D., Co-Founder of Restoration Biologics. “We highly value the patented technology developed by Enveric, and the confidence placed in our organization by Enveric,” said Dr. William D. Bugbee, Co-Founder and world-renown orthopedic surgeon and researcher in the joint restoration field at the Scripps Institute. Farsh Guilak, PhD, Chief Scientific Officer of Restoration Biologics and nationally recognized scientific leader in the field of regenerative medicine and joint pathology added, “Restoration Biologics appears uniquely positioned to achieve positive outcomes from this promising technology, and we look forward to its practical application to increase the successful treatment of patients, especially those suffering from joint disease.”
About Restoration Biologics LLC
Restoration Biologics is an early-stage R&D company developing joint restoration solutions using advanced bio-fabrication technologies and patient-specific regenerative medicine therapies to target musculoskeletal repair and pathologies. The company possesses deep technical expertise in the areas of cartilage restoration technology and cutting-edge regenerative medicine approaches.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric’s lead molecule, EB-003, is intended to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity and without also inducing hallucinations in the patient. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing all other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: successfully out-license patented PsybraryTM drug candidates to third-party licensees; negotiate and finalize definitive agreements based on any of its out-licensing term sheets and for licensees to perform pursuant to the terms thereof; finalize and submit its IND filing to the
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250128855986/en/
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Source: Enveric Biosciences
FAQ
What are the potential milestone payments for ENVB's licensing agreements with Restoration Biologics?
What royalty rates will ENVB receive from the Restoration Biologics licensing agreements?
What medical conditions will Restoration Biologics target with ENVB's licensed compounds?
What technology did ENVB license to Restoration Biologics?
